Items Tagged ‘treatment duration’

May 29, 2014

Updated Guidelines for Adjuvant Tamoxifen in Hormone-Positive Breast Cancer


The American Society of Clinical Oncology (ASCO) has updated their guidelines for the use of adjuvant endocrine therapy, particularly adjuvant tamoxifen (Nolvadex®), for women with hormone receptor-positive breast cancer. This update, which focuses on duration of treatment, was published early online in the Journal of Clinical Oncology. A majority of breast cancers are estrogen receptor-positive (ER-positive), […]

View full entry

Tags: Breast Cancer, Carcinoma In Situ Breast cancer, News, Stage I Node Negative Breast Cancer, Stages II-III Breast Cancer, tamoxifen, treatment duration